Cymabay Therapeutics Inc
NASDAQ:CBAY 4:00:00 PM EDT
| Market Cap (Intraday) | 794.35M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $7.74 |
| 50-Day MA | $5.37 |
| 200-Day MA | $3.65 |
Cymabay Therapeutics Inc Stock, NASDAQ:CBAY
7575 Gateway Boulevard, Suite 110, Newark, California 94560
United States of America
Phone: +1.510.293.8800
Number of Employees: 59
Description
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.